Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05111626 |
|---|---|
| Brief Title: | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer (FORTITUDE-102) |
| First Submitted : | October 29, 2021 |
| First Submitted that Met QC Criteria : | October 29, 2021 |
| First Posted : | November 8, 2021 |
| Last Update Submitted that Met QC Criteria : | April 30, 2024 |
| Last Update Posted : | May 1, 2024 |